Tenecteplase in wake-up ischemic stroke trial: Protocol for a randomized-controlled trial by Roaldsen, Melinda Berg et al.
Protocol
Tenecteplase in wake-up ischemic
stroke trial: Protocol for a
randomized-controlled trial
Melinda B Roaldsen1,2 , Haakon Lindekleiv3, Agnethe Eltoft1,2,
Mirza Jusufovic4, Mary-Helen Søyland5, Jesper Petersson6,
Bent Indredavik7, Arnstein Tveiten5, Jukka Putaala8,
Hanne Christensen9, Janika Kõrv10 , Dalius Jatužis11,
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Abstract
Background: Patients with wake-up ischemic stroke who have evidence of salvageable tissue on advanced imaging can
benefit from intravenous thrombolysis. It is not known whether patients who do not fulfil such imaging criteria might
benefit from treatment, but studies indicate that treatment based on non-contrast CT criteria may be safe. Tenecteplase
has shown promising results in patients with acute ischemic stroke. The aim of the Tenecteplase in Wake-up Ischemic
Stroke Trial (TWIST) is to compare the effect of thrombolytic treatment with tenecteplase and standard care versus
standard care alone in patients with wake-up ischemic stroke selected by non-contrast CT.
Methods/design: TWIST is an international, investigator-initiated, multi-centre, prospective, randomized-controlled,
open-label, blinded end-point trial of tenecteplase (n¼ 300) versus standard care (n¼ 300) in patients who wake up with
an acute ischemic stroke and can be treated within 4.5 h upon awakening. Seventy-seven centres in 10 countries
(Denmark, Estonia, Finland, Latvia, Lithuania, New Zealand, Norway, Sweden, Switzerland, and the United Kingdom)
participate. The primary outcome is the modified Rankin Scale on the ordinal scale (0–6) at three months.
Discussion: TWISTaims to determine the effect and safety of thrombolytic treatment with tenecteplase in patients with
wake-up ischemic stroke selected by non-contrast CT.
Trial registration: ClinicalTrials.gov NCT03181360. EudraCT Number 2014-000096-80.
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Thrombolytic treatment with intravenous recombinant
tissue plasminogen activator (rt-PA) given within 4.5 h
of onset improves clinical outcome after ischemic
stroke.1 About one in five ischemic strokes occur
during sleep,2 and these strokes have traditionally been
considered ineligible for thrombolytic treatment because
the time of onset is unknown. Recent trials have found
benefit of intravenous thrombolytic treatment with alte-
plase in patients with wake-up ischemic stroke (WUS)
and mismatch in lesion visibility between diffusion-
weighted imaging and fluid attenuation inversion recov-
ery (DWI/FLAIR mismatch) on MRI or signs of
penumbra on CT perfusion (CTP).3,4 Although
thrombolytic treatment has been shown to be effective
in patients who fulfil advanced imaging criteria, it is pos-
sible that thrombolysis will benefit patients without such
radiologic findings as well. Previous studies have shown
that DWI/FLAIR mismatch can be absent in as many as
40% of patients with known stroke duration of less than
3h,5 indicating that selection of patients based on
advanced imaging criteria could exclude WUS patients
who might benefit from thrombolysis. One-third of
patients who underwent screening for inclusion in the
WAKE-UP trial were excluded because they did not
fulfil mismatch criteria.3 Previous studies have shown
that clinical and radiological findings did not differ
between patients with WUS and patients with stroke
of known onset within 4.5 h.6 The limited availability
of emergency MRI and CTP in many hospitals may
also prevent patients from receiving treatment.
Thrombolytic treatment of WUS selected by non-con-
trast CT was found to be safe in two prospective, single-
armed open-label trials.7 A randomized-controlled trial
using routinely available brain imaging criteria to select
patients for treatment is therefore highly warranted.
Tenecteplase is genetically engineered to have
pharmacological advantages over alteplase and has a
simpler administration as it is given as a single bolus.8
A recent meta-analysis of five randomized controlled
trials showed strong evidence of tenecteplase being non-
inferior to alteplase for acute ischemic stroke.9 In one
randomized trial, tenecteplase was associated with a
higher incidence of reperfusion and improved clinical
outcome compared to alteplase.10
The aims of TWIST are to answer the following
questions:
. Can thrombolytic treatment with tenecteplase given
within 4.5 h of waking up with ischemic stroke using
non-contrast CT selection criteria improve func-
tional outcome at three months?
. Can findings on non-contrast CT identify patients
with wake-up ischemic stroke who benefit from
such treatment?
Methods and design
TWIST is a pragmatic, CT-based prospective, rando-
mized controlled, open-label trial with blinded end-point
assessment of intravenous thrombolysis with tenecteplase
in patients with acute ischemic stroke upon awakening.
Research ethics and regulatory approvals
The trial is conducted in accordance with the MRC
Guidelines for Good Clinical Practice in Clinical Trials,
the Council of Europe’s Convention on Human rights and
Biomedicine (CETS No.: 164), the ICH Harmonized
Tripartite Guideline for Good Clinical Practice (CPMP/
ICH/135/95), and the Declaration of Helsinki (Edinburgh,
October 2000). TWIST has received approval from med-
ical research ethical committees and medical agencies in all
10 participating countries. Written, informed consent is
obtained from all eligible patients according to approved
national regulations.
Patient population
We aim to include 600 patients (300 in each treatment
arm) with WUS who can be treated within 4.5 h after
awakening.
Inclusion and exclusion criteria
Inclusion criteria (simplified)
. Clinical diagnosis of stroke upon awakening (symp-
toms not present before sleep) with (i) limb weakness
and National Institutes of Health Stroke Scale
(NIHSS) score 3, or (ii) dysphasia.
. Treatment with tenecteplase is possible within 4.5 h
of awakening.
Exclusion criteria (simplified)
. Age <18 years.
. NIHSS score >25 or NIHSS consciousness score
>2, or seizures.
. Findings on non-contrast CT that indicate the
patient is unlikely to benefit from treatment:
Infarction comprising more than >1/3 of the
middle cerebral artery territory.
Intracranial hemorrhage.
. Active internal bleeding or high risk of bleeding (e.g.
major surgery, trauma, gastrointestinal or urinary tract
hemorrhage within 21 days, arterial puncture at non-
compressible site within 7 days, defect in coagulation,
known defect of clotting or platelet function).
The complete list of inclusion and exclusion criteria
is shown in Supplemental Material.
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Randomization
Patients are randomized in a 1:1 ratio using a central
computer-generated randomization schedule. The
schedule employs a minimization algorithm including
age, stroke severity (NIHSS), and time since wake-up
and is set to balance these characteristics across all
centres in all countries.
Intervention
The intervention group will be given tenecteplase
0.25mg per kg of body weight (maximum 25mg), as
an intravenous bolus, plus standard care, while the con-
trol group will be given standard care without thromb-
olysis with tenecteplase or any other thrombolytic
agent. Both treatment arms will receive best standard
care, including intra-arterial interventions for proximal
cerebral artery occlusion.
Clinical and radiological assessments
A timetable of clinical and radiological assessments is
shown in Table 1.
Findings on baseline non-contrast CT that will be
assessed are ASPECT Score, presence of early ischemic
changes (loss of grey/white matter cortex definition,
loss of basal ganglia outline, hypodensity, lesion
volume), and hyperdense artery presence and
localization.
Primary efficacy outcome
Functional outcome is defined by the mRS on the ordi-
nal scale (0–6) at three months.
Information on modified Rankin Scale (mRS) at
three months is obtained by centralized telephone inter-
view by trained and mRS-certified personnel blinded
for allocated treatment.
Secondary outcomes
Secondary effect outcomes include dichotomized mRS
score (0–1 vs. 2–6 and mRS 0–2 vs. 3–6), death from all
causes, symptomatic intracranial hemorrhage, any
intracranial hemorrhage, major extracranial bleeding,
recurrent ischemic stroke, NIHSS and change in
NIHSS score from baseline, EuroQol score (EQ-5D-
3L), mini-mental status examination score, and
health-economic variables at three months, in addition
to radiological outcomes at 24 h (see Supplemental
Material for complete list).
Data monitoring body
The Data Monitoring Committee (DMC) is regularly
performing unblinded reviews of SAEs in all patients.
An independent statistician prepares the data reports.
Only the DMC has access to the interim results. If evi-
dence of harm, or evidence of efficacy, the committee
will advise the chair of the Steering Committee.
Table 1. Examinations at baseline and follow-up
Days Months
1 2 7a 3
Time 1b Time 2c 30 min 1 h 3 h
Non-contrast CT x x x
CT angiography (x) x (x)
CT perfusion (x) (x)
NIHSS x x x
BP monitoring x x x x x x
mRS x x x
Centralized telephone interview x
Note: Day 1 is the day of entry into the trial.
aDay 7 or day of discharge, whichever occurs first.
bTime 1: at randomization.
cTime 2: at time of intervention/treatment.
BP: blood pressure; NIHSS: National Institutes of Health Stroke Scale; mRS: modified Rankin Scale; (x): optional examination which should not influence
the decision to include the patient, unless the results of the examination, according to the judgment of the investigator, show that the patient should or
should not receive thrombolytic treatment.
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The DMC will also be responsible for monitoring the
overall conduct of the trial, and may formulate recom-
mendations to improve adherence to protocol, manage-
ment, procedures, and quality control.
Sample size estimates
We assume a treatment effect of 10% absolute differ-
ence in a binary endpoint setting (mRS 0–1 vs. mRS 2–
6) and a distribution between modified Rankin Scale
categories similar to that of the WAKE-UP trial3
with 42% with favourable outcome in the non-throm-
bolysed group versus 52% in the thrombolysed group,
corresponding to an odds ratio of 1.50. Assuming an
effect size specified as an odds ratio of 1.5 from an
ordinal logistic regression model and similar distribu-
tion of mRS scores in the control group in six levels as
in the WAKE-UP trial (categories 5 and 6 merged) of
15%, 27%, 23%, 17%, 13%, and 5%3, the estimated
sample size of 600 patients yields a power of 80%, with
a two-sided significance level of 5%.
Statistical analyses
We will analyze the data according to the intention-
to-treat principle. Functional outcome will be
compared between the study groups by means of ordinal
logistic regression and adjusted for age, stroke severity
(baseline NIHSS), and time since wake-up. In secondary
analyses, favourable outcome defined as mRS 0–1 will
be compared by means of logistic regression with mRS
2–6, and good outcome defined as mRS 0–2 with mRS
3–6. A separate set of supplementary analyses will be
performed stratified by patients who received endovas-
cular treatment and those who did not.
For clinical event outcomes, we will estimate odds
ratios and 95% confidence intervals using logistic regres-
sion and estimate hazard ratios with corresponding 95%
confidence intervals using the Cox proportional hazards
model. All analyses will use 5% two-sided level of sig-
nificance. A detailed statistical analysis plan will be pub-
lished prior to end of recruitment.
Study organization and funding
The University Hospital of North Norway is the
Sponsor of the trial.
The main source of funding is from the Norwegian
Clinical Therapy Research in the Specialist Health
Services Research Programme. Additional grants are
from the Swiss Heart Foundation, the British Heart
Foundation, and the Norwegian National Association
for Public Health. The cost of tenecteplase is covered
by an unconditional grant from Boehringer Ingelheim
Norway KS.
Discussion
TWIST includes patients with wake-up stroke selected
by non-contrast CT and investigates whether these can
benefit from intravenous tenecteplase. The effect of
thrombolytic treatment in wake-up stroke patients
without mismatch criteria on MRI or CTP has not
been evaluated in previous randomized controlled clin-
ical trials. Although the rationale for using the specific
imaging criteria in the recent clinical trials of reperfu-
sion therapy is well funded theoretically, this cannot be
taken as evidence for lack of benefit from treatment in
patients without such criteria. DWI/FLAIR mismatch
can be absent in 40% of patients with known stroke
duration of less than 3 h.5 If treatment is offered only to
patients fulfilling the imaging criteria of the recent stu-
dies, many patients who might benefit from treatment
may be excluded. Furthermore, MRI is not available in
the emergency setting in many hospitals, and selection
based on non-contrast CT may increase access to treat-
ment and reduce delays.
Tenecteplase may potentially improve recanalization
compared to alteplase.11 The bolus administration and
the very rapid onset of action make tenecteplase an
attractive option for stroke patients and might possibly
reduce the time to recanalization of an occluded cere-
bral artery compared to alteplase.
We originally based our sample size estimation on
the results of a Cochrane systematic review of the
effect of rt-PA within 4.5 h of stroke onset,7 assessed
as a binary endpoint (favourable outcome mRS 0–2
versus mRS 3–6). As the primary endpoint in TWIST
is mRS across the full ordinal scale (shift analysis),
sample size estimation based on ordinal logistic regres-
sion analysis is more appropriate. The revised sample
size estimation is based on observations from recent
studies on thrombolytic treatment in patients with
wake-up stroke.12,13 Details are presented in the
Supplemental Material. As a result of the revised
sample size estimation, the target was increased from
500 to 600 patients. An even larger increase to account
for stroke mimics has not been deemed feasible in
light of drop in recruitment rate after the onset of
the Covid-19 pandemic as well as limited funding.
The TWIST study population is expected to reflect
real-life every day clinical practice. If successful,
TWIST may substantially increase the proportion of
WUS patients eligible for thrombolytic treatment.
Summary and conclusions
TWIST will show whether patients with wake-up
stroke can be treated with tenecteplase within
4.5 h of awakening, and whether non-contrast CT
can be used to identify patients who benefit from
treatment.
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